Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. Centers for Disease Control and Prevention. Preventing emerging infectious diseases: a strategy for the 21st century: overview of the updated CDC plan. MMWR. 1998;47(RR15):1-14.
2. Giblin TB, Sinkowitz-Cochran RL, Harris PL, et al. Clinicians' perceptions of the problem of antimicrobial resistance in health care facilities. Arch Intern Med. 2004;164(15):1662-1668.
4. Chouake J, Krausz A, Adler BL, Cohen HW, Nosanchuk JD, Friedman A. Management of cutaneous abscesses by dermatologists.J Drugs Dermatol. 2014;13(2):611-616.
5. Arroll B, Kenealy T, Kerse N. Do delayed prescriptions reduce antibiotic use in respiratory tract infections? A systematic review. Br J Gen Pract. 2003;53(496):871-877.
6. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev. 2005;19(4):CD003539.
7. Lin MY, Hayden MK. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: recognition and prevention in intensive care units. Crit Care Med. 2010;38(8 suppl):S335-S344.
8. Kerwat K, Kerwat M, Graf J, Wulf H. Resistance to antibiotics and multiresistant pathogens. Anasthesiol Intensivmed Notfallmed Schmerzther. 2010;45(4):242-243.
9. Centers for Disease Control and Prevention. Healthcare-Associated Infections. Available at https://www.cdc.gov/healthcare-associated-infections/?CDC_AAref_Val=https://www.cdc.gov/HAI/organisms/organisms.html. Last accessed February 24, 2026.
10. Siegel JD, Rhinehart E, Jackson M, Chiarello L, the Healthcare Infection Control Practices Advisory Committee. Management of Multidrug-Resistant Organisms in Healthcare Settings, 2006. Available at https://www.cdc.gov/infection-control/media/pdfs/guideline-mdro-h.pdf?CDC_AAref_Val=https://www.cdc.gov/infectioncontrol/pdf/guidelines/mdro-guidelines.pdf. Last accessed February 24, 2026.
11. Centers for Disease Control and Prevention. U.S. Action and Events to Combat Antimicrobial Resistance. Available at https://www.cdc.gov/antimicrobial-resistance/programs/ar-actions-events.html?CDC_AAref_Val=https://www.cdc.gov/drugresistance/us-activities.html. Last accessed February 24, 2026.
12. ASPE. National Action Plan for Combating Antibiotic-Resistant Bacteria, 20202025. Available at https://aspe.hhs.gov/reports/national-action-plan-combating-antibiotic-resistant-bacteria-2020-2025. Last accessed February 24, 2026.
13. Centers for Disease Control and Prevention. Antibiotic Use and Stewardship in the United States, 2025 Update: Progress and Opportunities. Available at https://www.cdc.gov/antibiotic-use/hcp/data-research/stewardship-report.html. Last accessed February 24, 2026.
14. Murray PR, Rosenthal KS, Pfaller MA (eds). Medical Microbiology. 9th edition. Philadelphia, PA: Elsevier; 2020.
15. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev. 2007;20(3):391-408.
16. Kaye KS, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am. 2000;14(2):293-319.
17. Stokowski LA. Antimicrobial Resistance: A Primer. Available at https://www.medscape.com/viewarticle/729196. Last accessed February 24, 2026.
18. Neu HC. Overview of mechanisms of bacterial resistance. Diagn Microbiol Infect Dis. 1989;12(4 Suppl 1):S109-S116.
19. Normark BH, Normark S. Evolution and spread of antibiotic resistance. J Intern Med. 2002;252(2):91-106.
20. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance. Guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997;18(4):275-291.
21. Centers for Disease Control and Prevention. Healthcare-Associated Infections (HAIs). HAI Pathogens and Antimicrobial Resistance Report 2018-2021. Available at https://www.cdc.gov/nhsn/hai-report/index.html. Last accessed February 24, 2026.
22. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Available at https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Last accessed February 24, 2026.
23. Goossens H. Antibiotic Resistance: Highlights of the 16th European Congress on Clinical Microbiology and Infectious Diseases. Available at https://www.medscape.org/viewarticle/530824. Last accessed February 24, 2026.
24. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2021-2022. Available at https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html. Last accessed February 24, 2026.
25. Centers for Disease Control and Prevention. Discovery of First mcr-1 Gene in E. coli Bacteria Found in a Human in United States. Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/media/releases/2016/s0531-mcr-1.html. Last accessed February 24, 2026.
26. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151-1161.
27. Centers for Disease Control and Prevention. CDC Health Advisory: Increase in Extensively Drug-Resistant Shigellosis in the United States. Available at https://www.cdc.gov/han/2023/han00486.html. Last accessed February 24, 2026.
28. Centers for Disease Control and Prevention. Antimicrobial Resistance Threats in the United States, 2021-2022. Available at https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html. Last accessed February 24, 2026.
29. Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA. 1996;275(4):300-304.
30. Centers for Disease Control and Prevention. About the National Antibiotic Resistance and Monitoring System (NARMS). Available at https://www.cdc.gov/narms/about/index.html. Last accessed February 24, 2026.
31. Pu S, Han F, Ge B. Isolation and characterization of methicillin-resistant Staphylococcus aureus strains from Louisiana retail meats. Appl Environ Microbiol. 2009;75(1):265-267.
32. Miao R, Wan C, Wang Z, et al. Inappropriate antibiotic prescriptions among pediatric inpatients in different type hospitals. Medicine (Baltimore). 2020;99(2):e18714.
33. Evans G. The day-care connection to drug resistance: parental pressure leads to antibiotic pressure. Healthcare Infect Prev. 2000:1-2.
34. Metlay JP, Powers JH, Dudley MN, Christiansen K, Finch RG. Antimicrobial drug resistance, regulation, and research. Emerg Infect Dis. 2006;12(2):183-190.
35. World Health Organization. Global Action Plan on Antimicrobial Resistance. Available at https://www.emro.who.int/health-topics/drug-resistance/global-action-plan.html. Last accessed February 24, 2026.
36. Centers for Disease Control and Prevention. 2022 Special Report: COVID-19 U.S. Impact on Antimircrobial Resistance. Available at https://www.cdc.gov/antimicrobial-resistance/media/pdfs/covid19-impact-report-508.pdf?CDC_AAref_Val=https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf. Last accessed February 24, 2026.
37. Centers for Disease Control and Prevention. Antimicrobial Resistance Facts and Stats. Available at https://www.cdc.gov/antimicrobial-resistance/data-research/facts-stats/index.html. Last accessed February 24, 2026.
38. Chen YY, Wang FD, Liu CY, Chou P. Incidence rate and variable cost of nosocomial infections in different types of intensive care units. Infect Control Hosp Epidemiol. 2009;30(1):39-46.
39. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA. 1996;275(3):234-240.
40. Mulvey MR, Grant JM, Plewes K, Roscoe D, Boyd DA. New Delhi metallo-ß-lactamase in Klebsiella pneumoniae and Escherichia coli, Canada. Emerg Infect Dis. 2011;17(1).
41. Rawat D, Nair D. Extended-spectrum ß-lactamases in gram negative bacteria. J Glob Infect Dis. 2010;2(3):263-274.
42. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis. 2001;32(Suppl 2):S114-S132.
43. Montgomery CP, Boyle-Vavra S, Adem PV, et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis. 2008;198(4):561-570.
44. McCaskill ML, Mason EO Jr, Kaplan SL, Hammerman W, Lamberth LB, Hulten KG. Increase of the USA300 clone among community-acquired methicillin-susceptible Staphylococcus aureus causing invasive infections. Pediatr Infect Dis J. 2007;26(12):1122-1127.
45. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, and participants in the Centers for Disease Control and Prevention-Convened Experts' Meeting on Management of MRSA in the Community. Strategies for Clinical Management of MRSA in the Community: Summary of an Experts' Meeting Convened by the Centers for Disease Control and Prevention. Atlanta, GA: Centers for Disease Control and Prevention; 2006.
46. Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001–2004. J Infect Dis. 2008;197(9):1226-1234.
47. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus (MRSA) Basics. Available at https://www.cdc.gov/mrsa/about/index.html. Last accessed February 24, 2026.
48. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–2004 influenza season. Emerg Infect Dis. 2006;12:894-899.
49. McCaig LF, McDonald LC, Mandal S. Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006;12(11).
50. Centers for Disease Control and Prevention. Clinical Overview of Methicillin-Resistant Staphylococcus aureus (MRSA) in Healthcare Settings. Available at https://www.cdc.gov/mrsa/hcp/clinical-overview/?CDC_AAref_Val=https://www.cdc.gov/mrsa/healthcare/index.html. Last accessed February 24, 2026.
51. Bratu S, Eramo A, Kopec R, et al. Community-associated methicillin-resistant Staphylococcus aureus in hospital nursery and maternity units. Emerg Infect Dis. 2005;11(6):808-813.
52. Healy CM, Hulten KG, Palazzi DL, Campbell JR, Baker CJ. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin Infect Dis. 2004;39(10):1460-1466.
53. Saiman L, O'Keefe M, Graham PL 3rd, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis. 2003;37(10):1313-1319.
54. Centers for Disease Control and Prevention. Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns—Chicago and Los Angeles County, 2004. MMWR. 2006;55(12):329-332.
55. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza: Louisiana and Georgia, December 2006–January 2007. MMWR. 2007;56(14):325-329.
56. Dean N. Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options. Hosp Pract (Minneap). 2010;38(1):7-15.
57. National Center for Infectious Diseases. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992 through June 2004, Issued October 2004. Available at https://www.cdc.gov/nhsn/PDFs/dataStat/NNIS_2004.pdf. Last accessed February 24, 2026.
58. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in U.S. intensive care units, 1997–2007. JAMA. 2009;301(7):727-736.
59. Elixhauser A, Steiner C. Infections with Methicillin-Resistant Staphylococcus aureus (MRSA) in U.S. Hospitals, 1993–2005. Available at https://www.hcup-us.ahrq.gov/reports/statbriefs/sb35.pdf. Last accessed February 24, 2026.
60. McAdam PR, Templeton KE, Edwards GF, et al. Molecular tracing of the emergence, adaptation, and transmission of hospital-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A. 2012;109(23):9107-9112.
61. Barnes SL, Harris AD, Golden BL, Wasil EA, Furuno JP. Contribution of interfacility patient movement to overall methicillin-resistant Staphylococcus aureus prevalence levels. Infect Control Hosp Epidemiol. 2011;32(11):1073-1078.
62. Selvey LA, Whitby M, Johnson B. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia: is it any worse than nosocomial methicillin-sensitive Staphylococcus aureus bacteremia? Infect Control Hosp Epidemiol. 2000;21(10):645-648.
63. Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007;28(3):273-279.
64. Wang FD, Chen YY, Chen TL, Liu CY. Risk factors and mortality in patients with nosocomial Staphylococcus aureus bacteremia. Am J Infect Control. 2008;36(2):118-122.
65. Centers for Disease Control and Prevention. Community-associated methicillin-resistant Staphylococcus aureus infections in Pacific Islanders—Hawaii, 2001–2003. MMWR. 2004;53(33):767-770.
66. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections in correctional facilities—Georgia, California, and Texas, 2001–2003. MMWR. 2003;52(41):992-996.
67. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants—Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000–2003. MMWR. 2003;52(33):793-795.
68. Zinderman CE, Conner B, Malakooti MA, LaMar JE, Armstrong A, Bohnker BK. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis. 2004;10(5):941-944.
69. Adcock PM, Pastor P, Medley F, Patterson JE, Murphy TV. Methicillin-resistant Staphylococcus aureus in two child care centers. J Infect Dis. 1998;178(2):577-580.
70. Lee NE, Taylor MM, Bancroft E, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis. 2005;40(10):1529-1534.
71. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA. 2001;286(10):1201-1205.
72. Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis. 2004;189(9):1565-1573.
73. D'Agata EM, Webb GF, Pressley J. Rapid emergency of co-colonization with community-acquired and hospital-acquired methicillin-resistant Staphylococcus aureus strains in the hospital setting. Math Model Nat Phenom. 2010;5(3):76-73.
74. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis. 2008;46(6):787-794.
75. Reich PJ, Boyle MG, Hogan PG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus strains in the neonatal intensive care unit: an infection prevention and patient safety challenge. Clin Microbiol Infect. 2016;22(7):645.
76. McCannon CJ, Hackbarth AD, Griffin FA. Miles to go: an introduction to the 5 Million Lives campaign. Jt Comm J Qual Patient Safe. 2007;33(8):477-484.
77. U.S. Department of Health and Human Services. HAI National Action Plan. Available at https://www.hhs.gov/oidp/topics/health-care-associated-infections/hai-action-plan/index.html. Last accessed February 24, 2026.
78. Centers for Disease Control and Prevention. Current HAI Progress Report. Available at https://www.cdc.gov/healthcare-associated-infections/php/data/progress-report.html?CDC_AAref_Val=https://www.cdc.gov/hai/data/portal/progress-report.html. Last accessed February 24, 2026.
79. Kourtis AP, Hatfield K, Baggs J, et al. Vital Signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections—United States. MMWR. 2019;68:214-210.
80. Khan TM, Kok YL, Bukhsh A, et al. Incidence of methicillin resistant Staphylococcus aureus (MRSA) in burn intensive care unit: a systematic review. Germs. 2018;8(3):113-125.
81. Makhni S, Umscheid CA, Soo J, et al. Hand hygiene compliance rate during the COVID-19 pandemic. JAMA Intern Med. 2021;181(7):1006-1008.
82. WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. Available at https://www.ncbi.nlm.nih.gov/books/NBK144035. Last accessed February 24, 2026.
83. Larson EL, Quiros D, Lin SX. Dissemination of the CDC's hand hygiene guideline and impact on infection rates. Am J Infect Control. 2007;35(10):666-675.
84. Fuller C, Savage J, Besser S, et al. "The dirty hand in the latex glove:" a study of hand hygiene compliance when gloves are worn. Infect Control Hosp Epidemiol. 2011;32(12):1194-1199.
85. Siegel JD, Rhinehart E, Jackson M, Chiarello L, the Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Available at https://www.cdc.gov/infection-control/media/pdfs/guideline-isolation-h.pdf?CDC_AAref_Val=https://www.cdc.gov/infectioncontrol/pdf/guidelines/isolation-guidelines-H.pdf. Last accessed February 24, 2026.
86. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureusand Enterococcus. Infect Cont Hosp Epidemiol. 2003;24(5):362-386.
87. Calfee DP, Salgado CD, Classen D, et al. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Cont Hosp Epidemiol. 2008;29(Suppl 1):S62-S80.
88. U.S. Food and Drug Administration. FDA Clears First Quick Test for Drug-Resistant Staph Infections [Archive]. Available at https://wayback.archive-it.org/7993/20170114031912/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm161552.htm. Last accessed February 24, 2026.
89. U.S. Food and Drug Administration. FDA Clears First Test to Quickly Diagnose and Distinguish MRSA and MSSA. Available at https://wayback.archive-it.org/7993/20170114063448/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254512.htm. Last accessed February 24, 2026.
90. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med. 2014;364(15):1419-1430.
91. Mergenhagen KA, Starr KE, Wattengel BA, Lesse AJ, Sumon Z, Sellick JA. Determining the utility of methicillin-resistant Staphylococcus aureus nares screening in antimicrobial stewardship. Clin Infect Dis. 2020;71(5):1142-1148.
92. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(1):1-38.
93. Saravolatz LD1, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012;55(4):582-586.
94. Centers for Disease Control and Prevention. About Vancomycin-Resistant Staphylococcus aureus. Available at https://www.cdc.gov/staphylococcus-aureus/about/vancomycin-resistant-staph.html?CDC_AAref_Val=https://www.cdc.gov/HAI/organisms/visa_vrsa/visa_vrsa.html. Last accessed February 24, 2026.
95. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010;50(6):821-825.
97. McManus AT, Goodwin CW, Pruitt BA Jr. Observations on the risk of resistance with the extended use of vancomycin. Arch Surg. 1998;133(11):1207-1211.
98. Furuno JP, McGregor JC, Harris AD, et al. Identifying groups at high risk for carriage of antibiotic-resistant bacteria. Arch Intern Med. 2006;166(5):580-585.
99. Centers for Disease Control and Prevention. Vancomycin-Resistant Enterococci (VRE) Basics. Available at https://www.cdc.gov/vre/about/?CDC_AAref_Val=https://www.cdc.gov/HAI/organisms/vre/vre.html. Last accessed February 24, 2026.
100. Squires RA, Postier RG. Tigecycline for the treatment of infections due to resistant gram-positive organisms. Expert Opin Investig Drugs. 2006;15(2):155-162.
101. U.S. Food and Drug Administration. FDA Drug Safety Communication: Increased Risk of Death with Tygacil (tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics. Last accessed February 24, 2026.
102. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Warns of Increased Risk of Death with IV Antibacterial Tycacil (tigecycline) and Approves New Boxed Warning. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline. Last accessed February 24, 2026.
103. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs. 2002;62(3):425-441.
104. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003;36(4):473-481.
105. Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother. 2004;53(4):646-649.
106. Fang FC, McClelland M, Guiney DG, et al. Value of molecular epidemiologic analysis in a nosocomial methicillin-resistant Staphylococcus aureus outbreak. JAMA. 1993;270(11):1323-1328.
107. Trindade PA, McCulloch JA, Oliveira GA, Mamizuka EM. Molecular techniques for MRSA typing: current issues and perspectives. Braz J Infect Dis. 2003;7(1):32-43.
108. Ross TL, Merz WG, Farkosh M, Carroll KC. Comparison of an automated repetitive sequence-based PCR microbial typing system to pulsed-field gel electrophoresis for analysis of outbreaks of methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43(11):5642-5647.
109. Levin TP, Byungse S, Axelrod P, Truant AL, Fekete T. Potential clindamycin resistance in clindamycin-susceptible, erythromycin-resistant Staphylococcus aureus: report of a clinical failure. Antimicrob Agents Chemother. 2005;49(3):1222.
110. Kader AA, Kumar A, Krishna A. Induction of clindamycin resistance in erythromycin-resistant, clindamycin susceptible and methicillin-resistant clinical staphylococcal isolates. Saudi Med J. 2005;26(12):1914-1917.
111. Gherardi G, De Florio L, Lorino G, Fico L, Dicuonzo G. Macrolide resistance genotypes and phenotypes among erythromycin-resistant clinical isolates of Staphylococcus aureus and coagulase-negative staphylocci, Italy. FEMS Immunol Med Microbiol. 2009;55(1):62-67.
112. Schmitz FJ, Sadurski R, Kray A, et al. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals. J Antimicrob Chemother. 2000;45(6):891-894.
113. Centers for Disease Control and Prevention. Clinical Features of Pneumococcal Disease. Available at https://www.cdc.gov/pneumococcal/hcp/clinical-signs/?CDC_AAref_Val=https://www.cdc.gov/pneumococcal/clinicians/clinical-features.html. Last accessed February 24, 2026.
114. Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine-Preventable Diseases: Chapter 11: Pneumococcal. Available at https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-11-pneumococcal.html. Last accessed February 24, 2026.
115. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System. Event Codes and Other Surveillance Resources. Available at https://ndc.services.cdc.gov/event-codes-other-surveillance-resources/. Last accessed February 24, 2026.
116. McCracken GH Jr. Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics. Pediatr Infect Dis J. 1995;14(5):424-428.
117. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.
118. Centers for Disease Control and Prevention. ABCs Report: Streptococcus pneumoniae, 2023. Available at https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2023.pdf.https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2020.pdf. Last accessed February 24, 2026.
120. Kietzman C, Tuomanen E. Acute bacterial meningitis: challenges to better antibiotic therapy. ACS Infect Dis. 2019;5(12):1987-1995.
121. Institute for Clinical Systems Improvement. Community-Acquired Pneumonia in Adults. Bloomington, MN: Institute for Clinical Systems Improvement; 2006.
122. Wodi AP, Issa AN, Moser CA, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 years or Older—United States, 2025. MMWR. 2025;74(2):30-33.
123. Centers for Disease Control and Prevention. Pneumococcal Vaccine Recommendations. Available at https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fvpd%2Fpneumo%2Fhcp%2Frecommendations.html. Last accessed February 24, 2026.
124. Matanock A, Lee G, Gierke R, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/= 65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR. 2019;68:1069-1075.
125. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791-1798.
126. Centers for Disease Control and Prevention. Facility Guidance for Control of Carbapenem-Resistant Enterobacteriaceae (CRE): November 2015 Update CRE Toolkit. Available at https://stacks.cdc.gov/view/cdc/79104. Last accessed February 24, 2026.
127. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228-236.
128. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multi-drug resistant infection. J Antimicrob Chemother. 2010;65(6):1119-1125.
129. Karampatakis T, Tsergouli K, Behzadi P. Carbapenem-resistant Klebsiella pneumoniae: virulence factors, molecular epidemiology and latest updates in treatment options. Antibiotics (Basel). 2023 Jan 21;12(2):234.
130. Cuzon G, Naas T, Nordmann P. KPC carbapenemases: what is at stake in clinical microbiology? Pathol Biol (Paris). 2010;58(1):39-45.
131. Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis. 2006;12(8):1209-1213.
132. Chen LF. Klebsiella pneumoniae Carbapenemase: Extended-Spectrum Beta-Lactamase Continues to Go Global. Available at https://www.medscape.com/viewarticle/587949. Last accessed February 24, 2026.
133. Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med J. 2011;104(1):40-45.
134. Giacobbe DR, Di Pilato V, Karaiskos I, et al. Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades. Ann Med. 2023;55(1):101-113.
135. Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011 Mar;37(3):244-247.
136. Barth N, Ribeiro VB, Zavascki AP. In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials. Antimicrob Agents Chemother. 2015;59(6):3596-3597.
137. Castanheira M, Sader HS, Mendes RE, Jones RN. Activity of plazomicin tested against enterobacterales isolates collected from U.S. hospitals in 2016-2017: effect of different breakpoint criteria on susceptibility rates among aminoglycosides. Antimicrob Agents Chemother. 2020;64(5):e02418-19.
138. Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019;79(3):271-289.
139. Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as rescue therapy for acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients. Clin Infect Dis. 2021;72(11):2021-2024.
140. Poirel L, Sadek M, Kusaksizoglu A, Nordmann P. Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants. Eur J Clin Microbiol Infect Dis. 2022;41(4):677-680.
141. Gaibani P, Bovo F, Bussini L, et al. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments. J Antimicrob Chemother. 2022;77(6):1570-1577.
142. Gaibani P, Lombardo D, Bussini L, et al. Epidemiology of meropenem/vaborbactam resistance in kpc-producing klebsiella pneumoniae causing bloodstream infections in northern Italy, 2018. Antibiotics (Basel). 2021;10(5):536.
143. Lexicomp Online. Available at https://online.lexi.com/lco/action/login. Last accessed February 24, 2026.
144. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024;ciae403.
145. Bassetti M, Righi E, Esposito S, Petrosillo N, Nicolini L. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol. 2008;3(6):649-660.
146. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis. 2010;23(4):332-339.
147. Gootz TD, Mara A. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect Ther. 2008;6(3):309-325.
148. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens. 2021;10(3):373.
149. Baran G, Erbay A, Bodur H, et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008;12(1):16-21.
150. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multidrug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis. 2007;26:793-800.
151. Jeong SH, Bae IK, Park KO, et al. Outbreaks of imipenem-resistant Acinetobacter baumannii producing carbapenemases in Korea. J Microbiol. 2006;44(4):423-431.
152. Nemec A, Krízová L, Maixnerová M, et al. Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant isolates of European clone II. J Antimicrob Chemother. 2008;62(3):484-489.
153. Chim H, Tan BH, Song C. Five-year review of infections in a burn intensive care unit: high incidence of Acinetobacter baumannii in a tropical climate. Burns. 2007;33(8):1008-1014.
154. Wang H, Guo P, Sun H, et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob Agents Chemother. 2007;51(11):4022-4028.
155. Mazumder SA. Acinetobacter. Available at https://emedicine.medscape.com/article/236891-overview. Last accessed February 24, 2026.
156. Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521-S528.
157. Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25(8):951-957.
158. Garnacho-Montero J, Timsit JF. Managing Acinetobacter baumannii infections. Curr Opin Infect Dis. 2019;32(1):69-76.
159. Centers for Disease Control and Prevention. About Pseudomonas aeruginosa. Available https://www.cdc.gov/pseudomonas-aeruginosa/about/?CDC_AAref_Val=https://www.cdc.gov/hai/organisms/pseudomonas.html. Last accessed February 24, 2026.
160. Todar K. Todar's Online Textbook of Bacteriology. Available at http://textbookofbacteriology.net/index.html. Last accessed February 24, 2026.
161. Centers for Disease Control and Prevention. Antimicrobial Resistance and Patient Safety Portal. Multidrug-Resistant Pseudomonas aeruginosa. Available at https://arpsp.cdc.gov/profile/antibiotic-resistance/mdr-pseudomonas-aeruginosa. Last accessed February 24, 2026.
162. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005;25(10):1353-1364.
163. Evans SR, Tran TTT, Hujer AM, et al. Rapid molecular diagnostics to inform empiric use of ceftazidime/avibactam and ceftolozane/tazobactam against Pseudomonas aeruginosa: PRIMERS IV. Clin Infect Dis. 2019;68(11):1823-1830.
164. Di Pasquale MF, Sotgiu G, Gramegna A, et al. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis. 2019;68(9):1482-1493.
165. Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187-212.
166. Centers for Disease Control and Prevention. Sexually Transmitted Infections Treatment Guidelines, 2021. Available at https://www.cdc.gov/std/treatment-guidelines/default.htm. Last accessed February 24, 2026.
167. Bala M, Sood S. Cephalosporin resistance in Neisseria gonorrhoeae. J Glob Infect Dis. 2010;2(3):284-290.
168. National Institute of Allergy and Infectious Diseases. Antimicrobial Resistance Threats. Available at https://www.niaid.nih.gov/research/antimicrobial-resistance-threats. Last accessed February 24, 2026.
169. Deguchi T, Nakane K, Yasuda M, Maeda S. Emergence and spread of drug resistant Neisseria gonorrhoeae. J Urol. 2010;184(3):851-858.
170. Centers for Disease Control and Prevention. About Gonorrhea. Available at https://www.cdc.gov/gonorrhea/about/index.html. Last accessed February 24, 2026.
171. U.S. Preventive Services Task Force. Chlamydia and Gonorrhea: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/chlamydia-and-gonorrhea-screening. Last accessed February 24, 2026.
172. Centers for Disease Control and Prevention. Update to CDC's Treatment Guidelines for Goncoccoal Infection, 2020. Available at https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm. Last accessed February 24, 2026.
173. Tsay S, Kallen A, Jackson BR, et al. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast. Clin Infect Dis. 2018;66:306-311.
174. Centers for Disease Control and Prevention. Candida auris. Available at https://www.cdc.gov/candida-auris/?CDC_AAref_Val=https://www.cdc.gov/fungal/candida-auris/index.html. Last accessed February 24, 2026.
175. Centers for Disease Control and Prevention, Candida auris: for Laboratory Professionals. Available at https://www.cdc.gov/candida-auris/hcp/index.html. Last accessed February 24, 2026.
176. Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134-140.
177. Centers for Disease Control and Prevention. Tuberculosis Data. Available at https://www.cdc.gov/tb-data/?CDC_AAref_Val=https://www.cdc.gov/tb/statistics/default.htm. Last accessed February 24, 2026.
178. Geiter L (ed). Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, DC: National Academy Press; 2000.
179. Reves RR, Nolan CM. Tuberculosis elimination in the United States: an achievable goal or an illusion? Am J Respir Crit Care Med. 2012;186(3):i-iii.
180. Centers for Disease Control and Prevention. Decrease in reported tuberculosis cases—United States, 2009. MMWR. 2010;59(10):289-294.
181. Centers for Disease Control and Prevention. Latent TB Infection in the United States, Published Estimates. Available at https://www.cdc.gov/tb-data/latent-tb-infection-estimates/?CDC_AAref_Val=https://www.cdc.gov/tb/statistics/ltbi.htm. Last accessed February 24, 2026.
182. Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA. 2005;293(22):2776-2784.
184. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis: an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200:e93-e142.
185. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR. 2005;54(RR17):1-147.
186. Centers for Disease Control and Prevention. About Drug-Resistant Tuberculosis Disease. Available at https://www.cdc.gov/tb/about/drug-resistant.html?CDC_AAref_Val=https://www.cdc.gov/tb/publications/factsheets/drtb/mdrtb.htm. Last accessed February 24, 2026.
187. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR. 2006;55(43):1176.
188. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994–2003. JAMA. 2005;293(22):2732-2739.
189. Telenti A, Iseman M. Drug-resistant tuberculosis: what do we do now? Drugs. 2000;59(2):171-179.
190. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR. 1994;43(RR13):1-132.
191. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195.
192. Centers for Disease Control and Prevention. Treating Inactive Tuberculosis. Available at https://www.cdc.gov/tb/treatment/inactive-tuberculosis.html. Last accessed February 24, 2026.
193. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, National Institutes of Health, HIV Medicine Association, and Infectious Diseases Society of America. 2023 Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available at https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new. Last accessed February 24, 2026.
194. Saukkonen JJ, Duarte R, Munsiff SS, et al. Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2025;211(1):15-33.
195. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrumβ-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):1109-1116.
196. Centers for Disease Control and Prevention. About ESBL-Producing Enterobacterales. Available at https://www.cdc.gov/esbl-producing-enterobacterales/about/?CDC_AAref_Val=https://www.cdc.gov/hai/organisms/ESBL.html. Last accessed February 24, 2026.
197. Centers for Disease Control and Prevention. Antimicrobial Resistance Solutions Initiative. Available at https://www.cdc.gov/antimicrobial-resistance/programs/?CDC_AAref_Val=https://www.cdc.gov/drugresistance/solutions-initiative. Last accessed February 24, 2026.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.